XML 47 R32.htm IDEA: XBRL DOCUMENT v3.8.0.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)
3 Months Ended 12 Months Ended
Sep. 30, 2016
USD ($)
Dec. 31, 2017
USD ($)
Number
Dec. 31, 2016
USD ($)
Dec. 31, 2015
USD ($)
Federal insurance limits   $ 250,000    
Write-off accounts receivable $ 2,200,000      
Number of issued patents | Number   18    
Advertising costs   $ 448,288 $ 752,611 $ 792,574
Shelf life of prescription products following product expiration   24 months    
Number of operating segment | Number   1    
Impact from modified retrospective basis adoption of accounting standard   $ 31,000    
Customer A [Member] | Accounts Receivable [Member]        
Concentration risk   27.00% 28.00%  
Customer B [Member] | Accounts Receivable [Member]        
Concentration risk   23.00% 20.00%  
Customer C [Member] | Accounts Receivable [Member]        
Concentration risk   22.00%    
Customer D [Member] | Accounts Receivable [Member]        
Concentration risk   11.00%    
Minimum [Member]        
Return period of unsalable prescription products   6 months    
Minimum [Member] | Software [Member]        
Estimated useful lives   5 years    
Maximum [Member]        
Return period of unsalable prescription products   12 months    
Maximum [Member] | Software [Member]        
Estimated useful lives   7 years    
Related to Research and Development Activities [Member]        
Advance payments - total   $ 0 $ 228,933